# OnCo record idea-fund-abbreviated-pathway-me-too-biologics (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-fund-abbreviated-pathway-me-too-biologics/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-fund-abbreviated-pathway-me-too-biologics" ;
  schema:name "An abbreviated approval path for follow-on antibodies within a validated class"@en ;
  schema:description "Once a class of antibody such as PD-1 blockers is proven, later copies could be approved on smaller trials showing equivalence, forcing price competition and freeing patients and money for genuinely new drugs."@en ;
  schema:url <https://onco.cc/ideas/idea-fund-abbreviated-pathway-me-too-biologics/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/d41573-022-00030-4> ;
  onco:related <https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/>, <https://onco.cc/ideas/idea-fund-head-to-head-mandate/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-incentive-misalignment/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/> .